1 **The ratio of left atrial and ventricular volume as new marker of atrial cardiopathy with**
2 **relevance for stroke risk and cognitive dysfunction**
3
4 Julian Deseoe[1,2], Martin Hänsel, MD[1], Lisa Herzog, PhD[1], Neda Davoudi, PhD[3,4], Andreas R. Luft,
5 MD[1,5], Catherine Gebhard, PhD[6], Bjoern Menze, PhD[4], Beate Sick, PhD[7,8], Susanne Wegener, MD[1,2*]
6
7
[1]Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich and
University of Zurich, Switzerland
[2]Neuroscience Center Zurich, University of Zurich, Zurich, Switzerland
[3]ETH Zurich, Institute for Biomedical Engineering, Department of Information Technology and
Electrical Engineering, Zurich, Switzerland
[4]Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland
[5]cereneo Center for Neurology and Rehabilitation, Vitznau, Switzerland
[6]Department of Cardiology, Inselspital University Hospital Bern, University of Bern, Bern Switzerland
[7]Epidemiology, Biostatistics & Prevention Institute, University of Zürich, Zürich, Switzerland
[8]TIDIT, Thurgau Institute for Digital Transformation, Kreuzlingen, Switzerland
18
19
20 Short title: LA:LV ratio is a marker for atrial cardiopathy
21
22
*Corresponding Author:
Susanne Wegener
Department of Neurology
University Hospital Zurich
Frauenklinikstrasse 26
8091 Zurich, Switzerland
Phone: +41 44 255 1111
Email: <u>Susanne.wegener@usz.ch</u>
31
32

33 Word counts: Abstract: 347 words; Main Manuscript: 3'024 words
34 Tables: 3; Figures: 4; References: 50

Abstract

Background: Atrial cardiopathy is an important cause of embolic stroke and a potential cause of cognitive dysfunction. Increased left atrial volume indexed to body surface area (LAVi) has been widely used as marker for atrial cardiopathy. However, since physiological remodeling may also increase LAVi, it lacks specificity. Left atrial to left ventricular volume (LA:LV) ratio was recently suggested as a better marker of atrial cardiopathy allowing a more accurate detection of imbalanced, pathological atrial remodeling. We investigated if LA:LV ratio is associated with different established sequelae of atrial cardiopathy and if it is superior to LAVi for the detection of atrial fibrillation/flutter (AF) as cause of stroke.

Methods: We compared the association of LAVi and LA:LV ratio with risk of ischemic stroke or transient ischemic attack (TIA) in the population-based UK Biobank cohort (n= 38'848), using cause specific hazard models. In addition, we tested for an association with cognitive function using multivariate linear regression models. Finally, we investigated the association of LAVi and LA:LV ratio with probability of atrial fibrillation/flutter being identified as stroke etiology in a cohort of ischemic stroke patients (n = 1'273). We compared the test performance of LAVi and LA:LV ratio for identifying atrial fibrillation/flutter as stroke etiology.

Results. While LAVi was not significantly associated with risk of ischemic stroke/TIA (HR: 1.11, 95% CI 0.97 - 1.26, p = 0.14), LA:LV ratio was (HR: 1.15, 95% CI 1.01-1.30, p = 0.04). Besides, LA:LV ratio was more strongly associated with worse cognitive function in healthy adults [LA:LV ratio: - 0.024 (95% CI (- 0.032) - (- 0.015)), LAVi: - 0.010 (95% CI (- 0.019) - (- 0.002))]. In a stroke patient cohort, LA:LV ratio showed a significantly better performance in identifying AF as underlying cause of ischemic stroke compared to LAVi (Receiver Operating Characteristic Area under the Curve 0.856 (0.803- 0.908) vs. 0.808 (0.750 - 0.866) p = 0.03).

Conclusions. We provide evidence that LA:LV ratio is a promising marker of atrial cardiopathy. Hence, LA:LV ratio has the potential to improve diagnosis of atrial cardiopathy, facilitating prevention of ischemic stroke and maintaining of brain health.

1. Introduction

Atrial cardiopathy is a structural and functional disorder of the atria, which is seen as both potential cause and consequence of atrial fibrillation (AF).[1] It has also been associated with higher risk of stroke[2] as well as lower cognitive performance,[3] even in the absence of AF. One leading explanatory hypothesis is that due to remodeling in atrial cardiopathy, thrombogenicity of the atria increases, leading to increased risk of stroke.[4] Similarly, cerebral micro-embolism due to atrial cardiopathy may lead to cognitive decline even in the absence of ischemic stroke.[3,5,6] Atrial cardiopathy has also been linked to cortical atrophy.[3] There is evidence that anticoagulation may reduce future ischemic strokes in patients with atrial cardiopathy, even in the absence of atrial fibrillation or flutter (AF).[7] However, the diagnosis of atrial cardiopathy in the absence of AF is not yet reliable enough to justify anticoagulation.

Although the importance of atrial cardiopathy is increasingly apparent, reliable methods for its diagnosis are still sparse.[4] Large left atrial volume indexed to body surface area (LAVi) has been commonly used as an indicator of atrial cardiopathy.[8] Increased LAVi has been associated with increased risk of ischemic stroke[9-11] and poorer cognitive function,[3,12,13] although there has been variation between studies. In clinical practice, increased LAVi can indicate ischemic stroke patients with high likelihood of AF as underlying stroke cause.[14]

However, the use of LAVi for the detection of atrial cardiopathy has important limitations. Physiological remodeling of the left atrium, for example due to physical activity, can also lead to increased LAVi complicating its use as a marker of pathological remodeling.[15-19] Recently, the left atrial to ventricular volume (LA:LV) ratio, defined as the ratio between the maximal left atrial volume at end systole and left ventricular end diastolic volume (LVEDV) has been proposed to better differentiate between balanced, physiological and imbalanced, pathological left atrial enlargement.[19-21] This is based on the observation that physiological remodeling, such as that induced by exercise, typically results in proportional increases in both left atrial volume and left ventricular volume, thereby maintaining a relatively stable LA:LV rato.[15-17,19] However, associations of LA:LV ratio with known sequelae of atrial cardiopathy impacting brain health have never been systematically studied.

We aimed to compare LA:LV ratio and LAVi as markers of atrial cardiopathy, by investigating their

associations with different sequelae of atrial cardiopathy. First, we evaluated the associations of

LAVi and LA:LV ratio with the risk of ischemic stroke or transient ischemic attack (TIA), cognitive

function and cortical atrophy in subpopulations of the population-based UK Biobank (UKBB) cohort.

Second, we examined the predictive performance of LAVi and LA:LV ratio for identifying AF as the

underlying cause of stroke in a clinical cohort of ischemic stroke patients from the University Hospital

Zurich (USZ).

2. Methods

Association between left atrial indices and risk of ischemic stroke/TIA, cognitive function

and cortical atrophy in the UKBB

The UKBB is a large population-based cohort study, which holds data of 502'128 participants from

the UK. The recruitment protocol is publicly available.[22] The UKBB imaging study contains among

other assessments, cardiac magnetic resonance (CMR) imaging for over 50'000 participants.[23] We

worked with the data release from March 2025 (v19). From the CMR imaging cardiac chamber

volumes have been previously extracted using deep learning and made accessible to researchers.[24]

LAVi and LA:LV ratio were standardized to have a mean of zero and a standard deviation of one to

facilitate comparison of effect sizes.

Participant selection

Data of all participants with available information on LA volume were considered for analysis. For

assessment of associations with risk of stroke/TIA, patients with AF diagnosed before the imaging

date, as well as patients with heart failure were excluded. Participants with AF were excluded as

quantification of cardiac volumes with CMR in these patients can be imprecise.[25] Patients with heart

failure were excluded as the interplay between left atrial volume and left ventricular volume changes

in these patients.[26] Hence, these likely warrant a separate investigation. In addition, participants with

prior stroke or TIA were excluded. All participants with incomplete data were excluded. Details of

how participants with AF and heart failure were identified can be found in the supplemental

methods.

For assessment of association with cognitive function, the same inclusion and exclusion criteria

were applied with two exceptions. Patients with prior TIA were not excluded while those with

preexisting dementia were excluded. An overview of inclusion and exclusion of participants can

be found in Figure 1.

<u>Statistical Analysis</u>

All analyses were performed using R Studio with R version 4.4.0. Details on the definition of

endpoints can be found in the supplemental material. For assessment of associations of LAVi and

LA:LV with ischemic stroke/TIA risk, a competing risks analysis treating ischemic stroke/TIA and

death as competing events was performed. We calculated cause specific and subdistribution

hazard models[27] and performed the same regressions for the competing event, death. We

employed both unadjusted models and models adjusted for the covariates shown in Table 1.

Details on ascertainment of covariates can be found in the supplemental material and Table S1.

We tested for violation of the proportional hazard assumption by assessing Schoenfeld residuals.[28]

We investigated sex differences by including an interaction term between LA:LV ratio and sex and

LAVi and sex respectively in separate models.

Linear regression models were calculated to assess the association of LAVi and LA:LV ratio with

cognitive function, both in unadjusted and fully adjusted models. We investigated a potential nonlinear

association between LAVi or LA:LV ratio and cognitive function using restricted cubic spline with three

nodes.[29] Significance of nonlinear components was assessed using partial F test. Finally, we

investigated whether there was an interaction between sex and LAVi or sex and LA:LV ratio for the

association with cognitive function.

We then assessed the associations of LAVi and LA:LV ratio with magnetic resonance image

measured volumes of 66 cortical parcellations according to Desikan-Killiany parcellation[30] using linear

regression models adjusted for age, sex and intracranial volume. We adjusted for multiple testing

using the Benjamini-Hochberg procedure.[31] The temporal pole parcellation is not available in the

UKBB data due to its unreliable segmentation and was thus excluded. Details can be found in the

Supplemental Methods. We again excluded all participants with previous stroke, AF, heart failure or

missing data.

<u>Left atrial indices for detection of AF as cause of stroke in ischemic stroke patients from the USZ</u>

Data of all patients who had not refused consent for use of their routine data for research, treated for

ischemic stroke at the USZ in the years 2023 and 2024 were retrospectively collected. We received

permission from the Cantonal Ethics committee Zurich to perform this data collection (PREDICT,

BASEC-ID: PB_2016_01751). Cardiac volumes were extracted from echocardiography reports,

routinely performed after ischemic stroke. For the values to be included in the study, the

echocardiography had to be performed after the ischemic stroke diagnosis and before the outpatient

checkup at approximately three months after stroke. LAV was measured using the biplane method,

at the end of systole.[32,33] Patients with heart failure were once again excluded. Details can be found

in the supplemental methods.

Stroke etiology was identified from three-month checkup report if available or discharge report.

Similar to previous studies,[14] stroke etiology was categorized into three subgroups: 1) AF, 2) other

determined cause and 3) unknown etiology/incomplete workup. Detailed criteria are shown in Table

S2. Patients with unknown etiology or incomplete work up were excluded from the analysis. An

overview can be found in Figure 1.

Prior diseases reported in Table 2, BMI, age and sex were extracted from the Swiss Stroke registry.

<u>Statistical analysis</u>

Logistic regression models for the association of standardized LAVi and LA:LV ratio with AF being

identified as stroke cause were calculated for LAVi and LA:LV ratio, both in unadjusted models and

adjusting for age and sex. Area under the receiver operating characteristic curves (ROC-AUC) were

calculated for LAVi and LA:LV ratio for classifying stroke cause as either AF or other determined

stroke etiology and compared using DeLongs test.[34] Then, the ideal cut off point in our sample for

both parameters was calculated by maximizing the Youden index.[35] Using 10- fold cross validation,

sensitivity and specificity as well as positive and negative likelihood ratios were calculated for the

two parameters. We also evaluated predictive performance in male and female patients separately.

Finally, we investigated if LA:LV ratio held complimentary information to MR proANP, a blood

biomarker, which is also used to indicate atrial cardiopathy.[36] Details can be found in the

supplemental material.

3. Results

Figure 1 shows the inclusion/exclusion flow chart for participants included into this study. For the

analysis of atrial indices and risk of ischemic stroke/TIA, 26'955 participants were included. For

analysis of cognitive function, 17'133 participants were included. Although both analyses started with

the same initial UKBB dataset, a substantial number of participants lacked complete cognitive

assessments, resulting in a smaller final sample size. A summary of cohort characteristics is shown

in Table 1.

Cardiac chamber volumes as measured by echocardiography in the clinical cohort were smaller

compared to the UKBB cohort (LAVi: 38 ml/m^2 vs 32 ml/m^2, LVEDVi: 78 ml/m^2 vs 48 ml/m^2), which

is consistent with the known tendency of echocardiography, to underestimate chamber volumes

compared to CMR.[37]

We visually investigated the association of LAVi and LA:LV ratio with age, sex and everyday

physical activity (Figure 2). LAVi showed a positive association with physical activity. Women had

larger mean LA:LV ratios than men, while no such sex difference was observed for LAVi. LAVi has

been shown to be similar between sexes while men typically have larger LVEDVi, explaining our

findings.[38] These results were also confirmed using linear regression models (Tables S3-S4). To

account for potential sex differences, all subsequent analysis were controlled for sex and

investigated for sex specific effects. So cardiac volumes reported in this study confirmed findings

from existing literature.

We then investigated the association of LA:LV ratio and LAVi with risk of ischemic stroke/TIA. In the

UKBB cohort, LAVi was not significantly associated with incident ischemic stroke both in unadjusted

(Table S5) and fully adjusted models (Table 3). In contrast, larger LA:LV ratio was significantly

associated with an increased risk of future ischemic stroke/TIA (aHR 1.15, 1.01-1.30, p = 0.04).

When additionally including interaction terms with sex to the adjusted models, we observed no

significant interactions between sex and LAVi (p = 0.14) and sex and LA:LV ratio (p = 0.83),

meaning that there is no significant evidence for sex differences for these associations. No

significant associations were found between cardiac volumes and mortality (Table S6). Results for

subdistribution hazard models showed similar results (Tables S7-S8).

Atrial cardiopathy was previously found to be associated with cognitive decline and cortical atrophy,

potentially caused by cerebral microembolism.[3] Therefore, we tested for associations of LAVi and

LA:LV ratio with cognitive function. Larger LA:LV ratio was more strongly associated with poorer

cognitive function [Regression coefficient: - 0.024, 95% CI (- 0.032) - (- 0.015)] than LAVi

[Regression coefficient: - 0.010, 95%CI (- 0.019) - (- 0.002)] in fully adjusted (Table 3) and

unadjusted models (Table S5). No significant interactions for sex and LAVi (p = 0.83) or LA:LV ratio

(p = 0.70) were observed. We found no evidence of nonlinearity. (Figure S1).

Larger LA:LV ratio was associated with cortical atrophy especially in the temporal lobe, insula and

cingulate cortex. Associations with LAVi were partially present, but weaker (Figure 3, Supplemental

Data). Interestingly, atrophy in temporal lobe, insula and cingulate cortex have been previously

linked to AF and atrial cardiopathy,[39-40] so that the cortex-specific associations found with LA:LV ratio

could potentially represent an atrial cardiopathy related brain imaging phenotype.

Next, we examined the association of standardized LAVi and LA:LV ratio with the probability of AF

being identified as the cause of stroke in a cohort of 289 ischemic stroke patients from the USZ.

Results are shown in Table 3. Both standardized LAVi and LA:LV ratio were strongly associated with

AF as the stroke cause, with the effect size of LA:LV ratio being slightly larger in adjusted modes

(LA:LV ratio: Log Odds ratio: 1.7, 95% CI 1.1 – 2.3, p < 0.001, LAVi: Log Odds ratio: 1.4 95% CI 0.9

- 1.9, p < 0.001) and unadjusted models (Table S4). The LA:LV ratio showed a significantly higher

ROC-AUC compared to the LAVi for identifying AF as the stroke cause (0.856 (0.803 - 0.908) vs.

0.808 (0.750 - 0.866) p = 0.03) (Figure 4). LA:LV ratio outperformed LAVi on all calculated test

metrics (Table 3).

A sex stratified analysis showed that LA:LV ratio showed higher ROC-AUC for identifying AF as the

stroke cause than LAVi in both sexes. The ideal cut-off as calculated by the Youden Index was higher

for women compared to men (Women: 0.85 95% CI 0.69 – 0.96, Men: 0.71 95% CI 0.55 – 0.86),

(Table S9), which aligns with findings from the UKBB, were women showed higher average LA:LV

ratio.

Finally, we aimed to capture the effect of combining LA-LV with current clinical and blood biomarkers

for prediction of atrial cardiopathy. In a logistic regression model including LA:LV ratio, MR proANP,

age and sex, both higher MR proANP and higher LA:LV ratio were significantly associated with an

increased likelihood of AF as stroke cause. (Table S10) The multivariate model showed an improved

ROC-AUC for predicting AF as stroke cause (0.897, 95% CI 0.849 - 0.945) compared to LA:LV ratio

alone although the difference was not statistically significant. (p = 0.28). (Figure S2).

4. Discussion

We found that in different cohorts and independent of assessment modality (echocardiography

versus CMR), the LA:LV ratio consistently showed stronger associations than LAVi with clinically

relevant manifestations of atrial cardiopathy. In the UKBB, higher LA:LV ratios were linked to greater

risk of ischemic stroke/TIA and poorer cognitive function. Further, larger LA:LV ratio was significantly

associated with cortical atrophy especially in temporal lobe, insula and cingulate cortex, providing a

potential link between larger LA:LV ratio and worse cognitive function. In stroke patients, the LA:LV

ratio showed improved diagnostic performance for detecting AF as the stroke cause, with higher

ROC-AUCs in both sexes and sex-specific optimal cut-offs.

Our findings align with our hypothesis that LA:LV ratio is more strongly associated with sequelae of

atrial cardiopathy than LAVi and show its potential as a marker for atrial cardiopathy. We

hypothesize that this is because it addresses key limitations of LAVi for assessing atrial cardiopathy

as it allows improved detection of imbalanced, pathological cardiac remodeling

There is abundant evidence that left atrial, and the left ventricular function are interdependent.[41] For

example, changes in left atrial function influence left ventricular filling pressure and vice versa.[41.42]

The complex interplay of left atrium and ventricle is not captured by measuring LAVi alone. In

contrast, while no single marker could ever fully characterize these interactions, the LA:LV ratio is a

straightforward way of assessing the left atrium, while incorporating information from the left

ventricle.

We hypothesize that, as it allows joint assessment the left atrium and ventricle, the LA:LV ratio can

better distinguish between balanced and unbalanced cardiac remodeling. While there is little

literature directly comparing the effects of balanced and unbalanced atrial remodeling on the risk of

cardiovascular events, there is some evidence comparing the effects of left atrial enlargement (LAE)

in physically active and inactive people. Participants with LAE who were physically active, had a

significantly lower risk of AF compared to inactive participants with LAE.[43] Further, physical activity

has been associated with reduced risk of AF and stroke.[44,45] Therefore, an increased LAVi with

unchanged or decreased LVEDVi may better represent an atrial cardiopathy phenotype, which

would be associated with increased risk of stroke, worse cognitive function and increased probability

of AF as stroke cause. Large LAVi coupled with increased LVEDVi, on the other hand, may be more

representative of physiological changes, e.g. induced by increased physical activity, and thus less

indicative of adverse cardiovascular events. However, more, especially longitudinal studies are

needed to further investigate this hypothesis.

The LA:LV ratio could easily be incorporated into clinical practice, since the required measures LAVi

and LVEDVi are routinely obtained in echocardiography or cardiac imaging. We demonstrate this by

validating LA:LV ratio in a clinical cohort. In patients with ischemic stroke, early detection of atrial

cardiopathy is essential, as patients with atrial fibrillation require anticoagulation to be adequately

protected from stroke recurrence.[46] LA:LV ratio could improve selection of patients for long term

rhythm monitoring to detect underlying AF. Increased LA:LV ratio might even become a sufficient

justification for prescribing anticoagulation in ischemic stroke patients, especially in patients, where

no other convincing stroke etiology is found, as atrial cardiopathy can lead to cardioembolic stroke

even in the absence of AF.[7] Hence, this study should inspire prospective multicenter trials to

facilitate the establishment of LA:LV ratio in clinical practice, especially as part of diagnostic work-up

of ischemic stroke.

Limitations

Due to the large sample size of the UKBB, statistically significant but not clinically relevant

associations might be detected. This is especially a potential limitation for associations of LA:LV ratio

with ischemic stroke/TIA in the UKBB cohort, where effect size was only borderline significant. We

addressed this by also evaluating LAVi and LA:LV ratio in a smaller clinical cohort. Another limitation

of our study is that we deliberately excluded subjects with heart failure, reduced EF and LV dilation,

as interaction between LAVi and LVEDVi are different in these patients. These subjects should be

studied in dedicated cohorts. Finally, although longitudinal studies have been conducted on effects of

exercise on heart volumes,[15-17,19] supporting our mechanistic hypothesis, establishing causality is not

possible with an observational, cross-sectional approach. Further, it would have been interesting to

correlate and compare LA:LV ratio with other proposed imaging markers of atrial cardiopathy such as

left atrial strain.[47] However, left atrial strain was not measured in the UKBB imaging protocol and is

not routinely measured in clinical practice at the University Hospital Zurich.

Conclusions

We show that LA:LV is a promising new marker of atrial cardiopathy and demonstrate its

associations with clinically relevant manifestations of atrial cardiopathy. Further, we show its

potential value for guiding diagnostic workup post ischemic stroke. Prospective, multicenter studies

are needed to further validate our findings and establish sex specific reference values to facilitate

the use of LA:LV ratio in clinical practice.

5. Acknowledgements

This research has been conducted using the UK Biobank Resource under application number

467527. This work uses data provided by patients and collected by the NHS as part of their care

and support. The clinical data analyzed in this study will be made available upon reasonable

request. Figure layout was created using Biorender

6. Data Availability Statement

The UK Biobank will make the data available to all bona fide researchers for all types of health-

related research that is in the public interest. For more details on the access procedure, see the

UK Biobank website: http://www.ukbiobank.ac.uk/register-apply/. Anonymized data from the

University Hospital Zurich not published within this article will be made available by request from

any qualified investigator.

6. Sources of Funding

This work was supported by the UK Biobank Platform Credits Programme for covering

computational costs, and the Swiss National Science Foundation (SNSF 310030_200703) and

the UZH Candoc Grant (25-024)

7. Disclosures

None

8. Supplemental Material

Detailed Methods

Tables S1-S10

Figures S1-S2

Supplemental Data

9. References

1. Goette A, Lendeckel U. Atrial Cardiomyopathy: Pathophysiology and Clinical Consequences. Cells. Sep 30 2021;10(10)doi:10.3390/cells10102605

2. Edwards JD, Healey JS, Fang J, Yip K, Gladstone DJ. Atrial Cardiopathy in the Absence of Atrial Fibrillation Increases Risk of Ischemic Stroke, Incident Atrial Fibrillation, and Mortality and Improves Stroke Risk Prediction. J Am Heart Assoc. Jun 2 2020;9(11):e013227. doi:10.1161/jaha.119.013227

3. Myers SJ, Jiménez-Ruiz A, Sposato LA, Whitehead SN. Atrial cardiopathy and cognitive impairment. Front Aging Neurosci. 2022;14:914360. doi:10.3389/fnagi.2022.914360Zhang JC, Bhat A. Atrial Cardiopathy: Redefining Stroke Risk Beyond Atrial Fibrillation. The American Journal of Cardiology. August 2023;201:177–84.

4. Zhang JC, Bhat A. Atrial Cardiopathy: Redefining Stroke Risk Beyond Atrial Fibrillation. Am J Cardiol. Aug 15 2023;201:177-184. doi:10.1016/j.amjcard.2023.06.002

5. Johansen MC, Wang W, Zhang M, et al. Risk of Dementia Associated With Atrial Cardiopathy: The ARIC Study. J Am Heart Assoc. Aug 16 2022;11(16):e025646. doi:10.1161/jaha.121.025646.

6. Wang W, Zhang MJ, Inciardi RM, et al. Association of Echocardiographic Measures of Left Atrial Function and Size With Incident Dementia. Jama. Mar 22 2022;327(12):1138-1148. doi:10.1001/jama.2022.2518

7. Healey JS, Gladstone DJ, Swaminathan B, et al. Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol. Jul 1 2019;76(7):764-773. doi:10.1001/jamaneurol.2019.0617

8. Kamel H, Okin PM, Longstreth WT, Jr., Elkind MS, Soliman EZ. Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol. May 2015;11(3):323-31. doi:10.2217/fca.15.22

9. Overvad TF, Nielsen PB, Larsen TB, Søgaard P. Left atrial size and risk of stroke in patients in sinus rhythm. A systematic review. Thromb Haemost. Aug 1 2016;116(2):206-19. doi:10.1160/th15-12-0923

10.   Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic

stroke in an ethnically mixed population. Stroke. Oct 1999;30(10):2019-24.

doi:10.1161/01.str.30.10.2019

11.   Larsen BS, Olsen FJ, Andersen DM, et al. Left Atrial Volumes and Function, and Long-Term

Incidence of Ischemic Stroke in the General Population. J Am Heart Assoc. Sep 20

2022;11(18):e027031. doi:10.1161/jaha.122.027031

12.   Alosco ML, Gunstad J, Jerskey BA, et al. Left atrial size is independently associated with

cognitive function. Int J Neurosci. Aug 2013;123(8):544-52.

doi:10.3109/00207454.2013.774396

13.   Gonzalez Casanova I, Alonso-Gómez Á M, Romaguera D, et al. Association of Left Atrial

Structure and Function With Cognitive Function in Adults With Metabolic Syndrome. Am J

Cardiol. Nov 15 2022;183:122-128. doi:10.1016/j.amjcard.2022.08.006

14.   Jordan K, Yaghi S, Poppas A, et al. Left Atrial Volume Index Is Associated With

Cardioembolic Stroke and Atrial Fibrillation Detection After Embolic Stroke of

Undetermined Source. Stroke. Aug 2019;50(8):1997-2001.

doi:10.1161/strokeaha.119.025384

15.   McNamara DA, Aiad N, Howden E, et al. Left Atrial Electromechanical Remodeling

Following 2 Years of High-Intensity Exercise Training in Sedentary Middle-Aged Adults.

Circulation. Mar 19 2019;139(12):1507-1516. doi:10.1161/circulationaha.118.037615

16.   Opondo MA, Aiad N, Cain MA, et al. Does High-Intensity Endurance Training Increase the

Risk of Atrial Fibrillation? A Longitudinal Study of Left Atrial Structure and Function. Circ

Arrhythm Electrophysiol. May 2018;11(5):e005598. doi:10.1161/circep.117.005598

17.   Kyrouac D, Talbot N, MacNamara J, et al. Effects of Year Long Aerobic Exercise on Left

Atrial Size in Patients With Left Ventricular Hypertrophy. Am J Cardiol. Jun 1 2025;244:3-8.

doi:10.1016/j.amjcard.2025.02.020

18.   Letnes JM, Nes B, Vaardal-Lunde K, et al. Left Atrial Volume, Cardiorespiratory Fitness,

and Diastolic Function in Healthy Individuals: The HUNT Study, Norway. J Am Heart Assoc.

Feb 4 2020;9(3):e014682. doi:10.1161/jaha.119.014682.

19.   Spencer LW, Moura Ferreira S, Milani M, et al. Left atrioventricular ratio (LA:LV): Using left

ventricular size as the reference for identifying maladaptive left atrial remodelling. Eur Heart J

Cardiovasc Imaging. Nov 27 2025;doi:10.1093/ehjci/jeaf333

20.   Spencer LW, D'Ambrosio P, Ohanian M, et al. Atrial cardiomyopathy in endurance

athletes. npj Cardiovascular Health. 2024/11/21 2024;1(1):30. doi:10.1038/s44325-024-

00032-8

21.   Sabo S, Dalen H, Nyberg J, et al. Left atrial to ventricular volume ratio and relation to

fitness, cardiovascular risk factors, and diastolic function in healthy individuals: the HUNT

Study. Eur Heart J Imaging Methods Pract. Jan 2024;2(1):qyae028.

doi:10.1093/ehjimp/qyae028.

22.   UK Biobank: Protocol for a Large-Scale Prospective Epidemiological Resource, 2007. https://

www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol. pdf (06 February

2025, date last accessed)

23.   Petersen SE, Matthews PM, Francis JM, et al. UK Biobank's cardiovascular magnetic

resonance protocol. J Cardiovasc Magn Reson. Feb 1 2016;18:8. doi:10.1186/s12968-016-

0227-4

24.   Bai W, Suzuki H, Huang J, Francis C, Wang S, Tarroni G, et al. A population-based

phenome-wide association study of cardiac and aortic structure and function. Nat Med.

2020;26(10):1654-62.

25.   Laubrock K, von Loesch T, Steinmetz M, et al. Imaging of arrhythmia: Real-time cardiac

magnetic resonance imaging in atrial fibrillation. Eur J Radiol Open. 2022;9:100404.

doi:10.1016/j.ejro.2022.100404

26.   Melenovsky V, Hwang SJ, Redfield MM, Zakeri R, Lin G, Borlaug BA. Left atrial

remodeling and function in advanced heart failure with preserved or reduced ejection

fraction. Circ Heart Fail. Mar 2015;8(2):295-303. doi:10.1161/circheartfailure.114.001667.

27.   Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J

Epidemiol. July 2009;170(2):244–56.

28.   P. Grambsch and T. Therneau (1994), Proportional hazards tests and diagnostics based

on weighted residuals. *Biometrika,* **81**, 515-26

29.   Lenth RV. Response-Surface Methods in R, Using rsm. Journal of Statistical

Software. 2010;32:1–17.1

30.   Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the

human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. Jul 1

2006;31(3):968-80. doi:10.1016/j.neuroimage.2006.01.021

31.   Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful

Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B

(Methodological). 1995;57(1):289-300.

32.   Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber

quantification by echocardiography in adults: an update from the American Society of

Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc

Echocardiogr. Jan 2015;28(1):1-39.e14. doi:10.1016/j.echo.2014.10.003

33.   Nagueh SF, Sanborn DY, Oh JK, et al. Recommendations for the Evaluation of Left

Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved

Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography. J

Am Soc Echocardiogr. Jul 2025;38(7):537-569. doi:10.1016/j.echo.2025.03.011

34.   DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more

correlated receiver operating characteristic curves: a nonparametric approach. Biometrics.

Sep 1988;44(3):837-45.

35.   Schisterman EF, Faraggi D, Reiser B, Hu J. Youden Index and the optimal threshold for

markers with mass at zero. Stat Med. 2008;27(2):297-315.

36.   Schweizer J, Arnold M, König IR, et al. Measurement of Midregional Pro-Atrial

Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke. J Am

Coll Cardiol. Apr 12 2022;79(14):1369-1381. doi:10.1016/j.jacc.2022.01.042

37.   Zhao D, Quill GM, Gilbert K, Wang VY, Houle HC, Legget ME, et al. Systematic Comparison

of Left Ventricular Geometry Between 3D-Echocardiography and Cardiac Magnetic Resonance

Imaging. Front Cardiovasc Med. 2021;8:728205.

38.   Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, et al. Reference ranges ("normal values")

for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc

Magn Reson. Dec 14 2020;22(1):87. doi:10.1186/s12968-020-00683-3

39.   Liao GZ, He CH, Li XQ, et al. Exploring the heart-brain and brain-heart axes: Insights from a

bidirectional Mendelian randomization study on brain cortical structure and cardiovascular disease.

Neurobiol Dis. Oct 1 2024;200:106636. doi:10.1016/j.nbd.2024.

40.   Huang LJ, Chen JS, Song YZ, Chang P. Atrial fibrillation and cognitive impairment:

mechanisms, influencing factors, and prospects. Front Cardiovasc Med. 2025;12:1527802.

doi:10.3389/fcvm.2025.1527802

41.   Ferkh A, Clark A, Thomas L. Left atrial phasic function: physiology, clinical assessment and

prognostic value. Heart. Oct 26 2023;109(22):1661-1669. doi:10.1136/heartjnl-2022-321609

42.   Pergola V, D'Andrea A, Galzerano D, et al. Unveiling the Hidden Chamber: Exploring the

Importance of Left Atrial Function and Filling Pressure in Cardiovascular Health. J Cardiovasc

Echogr. Jul-Sep 2023;33(3):117-124. doi:10.4103/jcecho.jcecho_44_23

43.   Heitmann KA, Løchen ML, Stylidis M, Hopstock LA, Schirmer H, Morseth B. Associations

between physical activity, left atrial size and incident atrial fibrillation: the Tromsø Study 1994-

2016. Open Heart. Jan 2022;9(1)doi:10.1136/openhrt-2021-001823

44.   Elliott AD, Linz D, Mishima R, et al. Association between physical activity and risk of incident

arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort. Eur Heart J. Apr 14

2020;41(15):1479-1486. doi:10.1093/eurheartj/ehz897.

45.   Jin MN, Yang PS, Song C, et al. Physical Activity and Risk of Atrial Fibrillation: A Nationwide

Cohort Study in General Population. Sci Rep. Sep 13 2019;9(1):13270. doi:10.1038/s41598-

019-49686-w

46.   Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in

Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart

Association/American Stroke Association. Stroke. Jul 2021;52(7):e364-e467.

doi:10.1161/str.0000000000000375

47.   Marincheva G, Iakobishvili Z, Valdman A, Laish-Farkash A. Left Atrial Strain: Clinical Use and

Future Applications-A Focused Review Article. Rev Cardiovasc Med. May 2022;23(5):154.

doi:10.31083/j.rcm2305154

Supplementary References

489
48.   Petersen M, Chevalier C, Naegele FL, Ingwersen T, Omidvarnia A, Hoffstaedter F, et

al. Mapping the interplay of atrial fibrillation, brain structure, and cognitive dysfunction.

Alzheimers Dement. 2024;20(7):4512-26.

49.   Fawns-Ritchie C, Deary IJ. Reliability and validity of the UK Biobank cognitive tests.

PLoS One. 2020;15(4):e0231627.

50.   Huang YT, Wei T, Huang YL, Wu YP, Chan KA. Validation of diagnosis codes in healthcare

databases in Taiwan, a literature review. Pharmacoepidemiol Drug Saf. 2023;32(7):795-811.

497
498

10. Tables

	UKBB: Risk of Ischemic stroke/TIA[a]	UKBB: Cognitive function[b]	USZ Stroke patients: Stroke Etiology[c]	
			Non-AF	AF
n	26'955	17'133	213	76
Age (mean (SD))	63.52 (7.48)	63.81 (7.33)	60.24 (17.08)	74.87 (15.09)
Sex = Male (%)	12891 (47.8)	8280 (48.3)	135 (63.4)	30 (39.5)
LAVi [ml/m^2]	38.12 (10.21)	38.13 (10.29)	28.26 (7.99)	44.41 (17.83)
LA:LV ratio (mean (SD))	0.49 (0.12)	0.49 (0.12)	0.59 (0.19)	1.07 (0.49)
LVEDVi (mean (SD)) [ml/m^2]	77.84 (11.68)	77.78 (11.66)	49.62 (10.32)	43.31 (8.99)
Hypertension (%)	7358 (27.3)	4565 (26.6)	118 (55.4)	59 (77.6)
Diabetes (%)	1258 (4.7)	771 (4.5)	46 (21.6)	21 (27.6)
Vascular disease (%)	911 (3.4)	585 (3.4)	NA	NA
Dyslipidemia (%)	5475 (20.3)	3467 (20.2)	88 (41.3)	31 (40.8)
BMI (mean (SD)) [kg/m^2]	26.38 (4.30)	26.36 (4.34)	25.21 (4.11)	26.47 (4.34)
Physical Activity (%)			NA	NA
- high	12345 (45.8)	8043 (46.9)		
- moderate	3100 (11.5)	1843 (10.8)		
- low	11510 (42.7)	7247 (42.3)		
Smoking (%)[d]				
- never	17053 (63.3)	10989 (64.1)	141 (66.2)	66 (86.8)
- current	931 (3.5)	523 (3.1)	70 (32.9)	10 (13.2)
- previous	8971 (33.3)	5621 (32.8)		
Alcohol (%)			NA	NA
- Never	1658 (6.2)	1007 (5.9)		
- (almost) daily	4523 (16.8)	2814 (16.4)		
- 3-4 x a week	7209 (26.7)	4606 (26.9)		
- 1-2 x a week	3078 (11.4)	1975 (11.5)		
- 1-3 x times a month	2666 (9.9)	1636 (9.5)		
- Special occasions	7821 (29.0)	5095 (29.7)		
Townsend deprivation index (mean (SD))	-1.95 (2.68)	-1.95 (2.69)	NA	NA
University degree (%)		9196 (53.7)	NA	NA

500
501
502

Table 1. **Baseline Characteristics of the studied cohorts.** UKBB: UK Biobank, AF: Atrial

fibrillation/flutter, LAVi: left atrial volume indexed to body surface area, LVEDVi: left ventricular end-

diastolic volume indexed to body surface area, LA:LV ratio: left atrial to ventricular volume ratio. SD:

standard deviation

[a] "UKBB: Ischemic stroke" is a subpopulation of the UK Biobank cohort used for analysis of

association of ischemic stroke risk and atrial indices.

[b] "UKBB: Cognitive function" is a subpopulation of the UK Biobank used do assess association of

atrial indices and cognitive function.

[c] "USZ stroke patients: Stroke etiology" is a cohort of ischemic stroke patients from the USZ.

[d] For ischemic stroke patients, smoking status was only available classified as current/previous or

never. For two patients smoking status was not available.

Ischemic stroke/TIA [a]			
	Hazard ratio	95% CI	P -value
LAVi	1.11	0.97 - 1.26	0.14
LA:LV ratio	1.15	1.01 - 1.30	0.04
Cognitive function [b]			
	Coefficient	95% CI	P -value
LAVi	-0.01	(- 0.019) - (- 0.002)	0.02
LA:LV ratio	-0.024	(- 0.032) - (- 0.015)	< 0.001
Atrial fibrillation as cause of ischemic stroke [c]			
	Log Odds ratio	95% CI	P-value
LAVi	1.4	0.9 - 1.9	< 0.001
LA:LV ratio	1.7	1.2 - 2.3	< 0.001

Table 2. Associations of standardized left atrial volume index and standardized left atrial to left

ventricular volume ratio with sequelae of atrial cardiopathy. LAVi: left atrial volume index, LA:LV

ratio: left atrial to ventricular volume ratio

[a] Hazard ratios from cause specific hazard models for ischemic stroke with death as competing

event. HR > 1 indicate increased hazard rate of ischemic stroke/TIA. For LAVi and LA:LV ratio

two separate models were calculated each adjusted for the described covariates. 249

participants had an ischemic stroke/TIA as an endpoint (TIA: 88, ischemic stroke: 161), 606

deaths. Median time under observation was 6.8 years.

[b] Linear regression coefficients for cognitive function as independent variable. Coefficients > 0

indicate association of larger volumes with better cognitive function. For LAVi and LA:LV ratio two

separate models were calculated each adjusted for the described covariates.

[c] Log odds ratio for AF as stroke cause as independent variable in multivariate logistic regression.

Coefficients > 0 indicate association of larger volumes with AF as stoke cause. For LAVi and LA:LV

ratio two separate models were calculated each adjusted for age and sex. 289 ischemic stroke

patients included, 76 with atrial fibrillation as stroke cause.

	LA:LV ratio	LAVi
Optimal cut off point [a]	0.81 (0.68 - 0.87)	35 ml/m^2 (34 -36)
Sensitivity [b]	0.684 (0.573 -0.778)	0.658 (0.546 - 0.755)
Specificity [b]	0.850 (0.796 - 0.892)	0.808 (0.749 - 0.855)
LR + [b]	4.6 (3.3 - 6.7)	3.4 (2.5 - 4.8)
LR - [b]	0.37 (0.25 - 0.50)	0.42 (0.29 - 0.56)

536
Table 3. Test metrics of LA:LV ratio and LAVi for detecting atrial fibrillation as stroke cause

with 95% CI. LA:LV ratio: left atrial to ventricular volume ratio, LAVi: left atrial volume indexed to body

surface area, LR +: positive likelihood ratio, LR –: negative likelihood ratio

[a] Optimal cut o☐ calculated by maximizing Youden Index 95% CI calculated using 1000 bootstrap

samples.

[b] Test metrics calculated using 10-fold cross validation. 95% CI are Wilson CI.

544
545
546

547
548 **11. Figures**
549

550
551
552 **Figure 1. Inclusion flow chart**. LA: left atrium
553

Figure 2. (A) Association of Age, Sex and Activity with left atrial volume indexed to body
surface area. (B) Association of Age, Sex and Activity with left atrial to ventricular volume
ratio. Results from UK Biobank cohort used for ischemic stroke/TIA analysis. Blue lines show
linear regression lines. For LAVi and LA:LV ratio outliers more than three standard deviations from
the mean are not shown. Boxplots show mean (point) and median (line) values with interquartile
range. Values outside two standard deviations from the mean are not shown. LAVi: left atrial
volume indexed to body surface area, LA to LV ratio: left atrial to ventricular volume ratio, L: low,
M: medium, H: high.

Figure 3. (A) Associations of LAVi with cortical volumes according to Desikan-Killiany

parcellation. (B) Associations of LA:LV ratio with cortical volumes according to Desikan-

Killiany parcellation. Colors show significant (p < 0.05) regression coefficients for association of

standardized cortical volume with standardized LAVi/LA:LV ratio, adjusted for age, sex and

intracranial volume. Red regions show atrophy associated with larger LAVi/LA:LV ratio.

Parcellation of the temporal pole (grey) was not performed in the UK Biobank data due to

unreliable results. Analysis included 28'954 participants with available heart and brain imaging.

Plot created using python package pySimpleBrainPlot. LAVi: left atrial volume indexed to body

surface area, LA to LV ratio: left atrial to ventricular volume ratio.

AUC LA:LV ratio : 0.856 (0.803- 0.908)
AUC LAVi : 0.808 (0.750 - 0.866)
P = 0.03

578 **Figure 4. Receiver operating characteristic curves for LAVi and LA:LV ratio for detecting**

579 **atrial fibrillation as stroke cause**. Area under the curve with 95 % CI is shown in the bottom right.

580 Confidence intervals were calculated based on 1000 bootstrap samples. P value calculated with

581 DeLong's test. LAVi: Left atrial volume indexed to body surface area. LA:LV ratio: Left atrial to

582 ventricular volume ratio, ROC: Receiver operating characteristic, AUC: Area under the Curve.

583